[
    [
        {
            "time": "",
            "original_text": "中泰证券维持康泰生物买入评级：业绩基本符合预期，期待PCV13+HDCV",
            "features": {
                "keywords": [
                    "康泰生物",
                    "买入评级",
                    "业绩",
                    "PCV13",
                    "HDCV"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持康泰生物买入评级：业绩基本符合预期，期待PCV13+HDCV",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)：核心产品恢复放量 13价肺炎疫苗兑现再即",
            "features": {
                "keywords": [
                    "康泰生物",
                    "核心产品",
                    "放量",
                    "13价肺炎疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：核心产品恢复放量 13价肺炎疫苗兑现再即",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)：业绩略超预期 关注新冠放量及PCV13获批进展",
            "features": {
                "keywords": [
                    "康泰生物",
                    "业绩",
                    "新冠",
                    "PCV13",
                    "获批"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：业绩略超预期 关注新冠放量及PCV13获批进展",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)2021年中报点评：灭活新冠疫苗有望带来业绩增量 PCV13+二倍体狂苗值得期待",
            "features": {
                "keywords": [
                    "康泰生物",
                    "灭活新冠疫苗",
                    "业绩增量",
                    "PCV13",
                    "二倍体狂苗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)2021年中报点评：灭活新冠疫苗有望带来业绩增量 PCV13+二倍体狂苗值得期待",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601)：业绩符合预期 新冠疫苗贡献增量",
            "features": {
                "keywords": [
                    "康泰生物",
                    "业绩",
                    "新冠疫苗",
                    "增量"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物(300601)：业绩符合预期 新冠疫苗贡献增量",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]